Afternoon @kpaxSNT has only just popped up on my radar but with...

Afternoon @kpax

SNT has only just popped up on my radar but with circa $7m in cash and multiple Trials that are fully funded proposed I can only see the benefit for increased value from positive data ,,even one asset should send this upward..

This is not a normal margin trade for me ,,, Company are promoting topline results for December 2024 so 7 months at least but as you know the Phase II Sweet spot is one of my targets , recently completed a CR and I'm in under that price...

It would be unusual for a considerable amount of smart money to have shifted here and you know the level of Due Diligence those party's undertake.

Incredibly difficult to establish true value during this early discovery phase but delivering positive data well to the market can only benefit SH Value from here,,,, looks under valued from where I'm sitting... Burn /wound scaring reduction and bone scaffolding is highly visible and easily understood by investors, it is also swift to start delivering results and SNT are stating they have a specific date set for data release , 1st week of December at the American Society of Hematology... slot is booked .....

I look forward to your summary of what you discover deeper in the science. NZT